Articles tagged with Primary Tumors
A retrospective study published in Cancer journal shows an inverse correlation between the number of lymph nodes and 5-year survival rates. Patients with 20 or more tumor-free lymph nodes had a 4.33 times greater relative risk of dying from metastatic breast cancer, compared to those with fewer than 20.
A newly discovered gene in the pituitary gland is found to be activated by estrogen, leading to cell proliferation and tumor development. Researchers have identified this link between estrogen and pituitary tumor growth, which may lead to improved cancer diagnosis, assessment, and treatment.
Researchers at MGH discovered TGF-beta-1 inhibits blood vessel growth associated with metastatic gallbladder cancer. The study's results may lead to anti-angiogenesis agents for cancer treatment.
Researchers at Vanderbilt Cancer Center found that overproduction of TGF-beta contributes to tamoxifen resistance. They also discovered the importance of immune system's natural killer activity for tamoxifen's effectiveness. This discovery may lead to strategies to prolong tamoxifen response or even reverse resistance.
Researchers at Rockefeller University have found evidence of naturally occurring tumor immunity in humans, where the immune system targets a specific protein called cdr2 to fight cancer. This discovery provides support for immunotherapy treatments and offers new insights into cancer biology.
A new study found that patients with tumors expressing low levels of the tumor suppressor protein p21 are more likely to recur and die from bladder cancer than those with elevated p21 levels. The study suggests that knowing both p53 and p21 status is a more powerful indicator of risk, allowing for clearer treatment decisions.
Researchers developed a laser-based test to detect early-stage breast and prostate cancer by identifying epithelial cancer cells in blood samples. The test shows promise for predicting disease progression and monitoring treatment response.
A new strategy to treat and prevent tumors has been developed by University of Pittsburgh researchers using dendritic cells. The approach effectively prevents tumor development in healthy mice and reduces tumors in 80% of mice with established tumors, significantly prolonging their survival.
Researchers at Duke University Medical Center have found that a Tie2 inhibitor can significantly slow the growth of tumors on rats by preventing nearby blood vessels from forming capillaries to feed the cancer. The treatment slowed tumor growth by 75 percent and reduced vessel length density by 40 percent.
Researchers describe a powerful new immunotherapeutic approach that uses heat shock protein complexes to stimulate the immune system against cancer cells, with 80% of treated mice surviving longer than control mice. The treatment has potential for treating various cancers and may be applied in conjunction with surgery and chemotherapy.